Additionally, the placebo control group effects were eliminated from the sum effects to obtain the actual SGLT-2 inhibitors effects on UACR in T2DM patients, and Emax model was used to evaluate the effects of SGLT-2 inhibitors on UACR in T2DM patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.